Johns Hopkins Pain
@HopkinsPain
Followers
1K
Following
406
Media
38
Statuses
411
The Johns Hopkins Division of Pain Medicine offers safe, state of the art care to patients in pain by promoting strong clinical service, education and research.
Baltimore, MD
Joined October 2017
Online ahead of print in Molecular Pain: T cells shape paclitaxel-induced neuropathic pain in a modality- and phase-specific manner, with a selective role in cold hypersensitivity. https://t.co/KkbDZwMY7P
journals.sagepub.com
The role of T cells in chemotherapy-induced peripheral neuropathy (CIPN) is complex and shaped by biological and experimental factors, including sex, hormonal s...
1
3
5
Nearly 1 in 4 U.S. adults live with chronic pain. At Maimonides, we're proud to invest in patient-centered care that offers options beyond opioids. CNN's @drsanjaygupta features Dr. Sergey Motov & our ER team in It Doesn't Have to Hurt - Sept. 7, 9PM ET/PT. @maimoems @pained
8
3
4
"Take the time to listen and validate your patients’ pain experiences. Learning how the pain affects their daily activities may more precisely direct therapy."- @DoctorSivaMD @HopkinsPain @HopkinsACCM @RAPMOnline #MedTwitter
closler.org
By Eellan Sivanesan, MD, Johns Hopkins Medicine “I’m tired of explaining myself!” During an inpatient consult early in my career as a pain physician, I met a patient who had lived with severe...
1
6
10
Resiniferatoxin (RTX), a plant-derived compound, could pave the path for easing cancer-related pain. Recent NIH research shows that after a single injection of RTX, patients with advanced-stage cancer experienced a decrease in severe pain and the use of pain-relieving opioids.
9
24
129
Chronic pain remains a major challenge—despite scientific progress, many patients still face delays, stigma, and limited options. I spoke with @Newsweek about why better science hasn’t always led to better care. https://t.co/1K1LtXfTgA
#ChronicPain #PainResearch #HealthPolicy
newsweek.com
Science had its 'chronic Pain revolution.' So why is treatment still broken, delayed and out of reach?
5
9
14
💊 Lost in conversion? Converting intrathecal to oral opioids isn't as simple as 1:300. This RAPM case report shows: 🧩 Real-life ratios = 1:2 to 1:12 ⚠️ 1:300 may be dangerously outdated 🔗 https://t.co/1GV0V2A2TZ By @talktoratan @DoctorSivaMD
#Opioids #RAPM
1
12
15
#regionalanesthesia #pain
@ASRA_Society Consensus Practice Infection Control guidelines: 👇🏿 Check out: https://t.co/VY0huYEgIE
@DProvenzanoMD Full article: https://t.co/wiCDjpz6ey
@NarouzeMD @RAPMOnline @Ropivacaine @MayoPainMed @ESRA_Society @dr_tinadoshi @rakesh6282
0
23
39
It is unbelievable that when I started my lab 11 years ago people referred to itch as a "niche" therapeutic domain. Look at the monthly Rx of Ebglyss and Adbry (anti-IL-13 mAb) and Nemluvio (anti-IL-31RA mAb) since launch. Dupixent (anti-IL-4R mAb) is not on this chart because
4
9
69
Just arrived in my office-3rd edition of my book. New chapters, my original art, patient stories, and case studies. Available in September....#kathleensluka #slukaart #painscience @UIowaPTRS @uihealthcare @IowaMed @UIowaNeuro
5
14
74
What do you think the next step will be in mechanism-based nonopioid analgesic #painmanagement? Zeng et al. review the challenges and breakthroughs, as well as the need for pharmacodynamically distinct multimodal interventions in @jclinicalinvest
https://t.co/5RAnw515K8
#PRF
0
2
11
Nearly 19 million U.S. children—1 in 4—lived with at least one parent or primary caregiver who had a substance use disorder in 2023. The findings highlight the need for treatment for parents and interventions for families affected by substance use disorders.
nih.gov
Almost 19 million U.S. children—1 in 4—lived with at least one parent or primary caregiver who had a substance use disorder in 2023.
21
21
92
The @US_FDA has created a new program that will speed up the approval of new drugs before clinical trials are even completed, and without the usual oversight by FDA staff and advisors. What could possibly go wrong? @DrMakaryFDA
painnewsnetwork.org
By Crystal Lindell The U.S. Food and Drug Administration has launched a new speedy review process for new medications, dubbed the Commissioner’s National Priority Voucher (CNPV) program. The FDA...
1
6
14
So pleased this one now out with the amazing @DrSFink Interoception and pain: body–mind integration, rupture, and ... : PAIN
journals.lww.com
An abstract is unavailable.
0
12
26
Norepinephrine and CXCL16 are co-released from the terminals of sympathetic nerve fibres in the dorsal root ganglion & synergistically contribute to the maintenance of neuropathic pain #pain #laboratory #cytokines
https://t.co/HKbgmOI9U5
0
7
14
We are sad to announce that Dr. Ronald D. Miller has passed away. He served as our chair from 1984 until 2008, and was one of the most successful physician-scientist-leaders in the field’s history. Read more about his remarkable life and legacy: https://t.co/M2Y8yDdTSK
3
38
82
MEMBER SPOTLIGHT: @DoctorSivaMD is shaping the future of #neuromodulation! 🔬✨ As Director of Neuromodulation at @HopkinsMedicine, he is dedicated to leveraging #neurostimulation for patients with chronic pain & non-traditional indications. Read more: https://t.co/TmKanqYzLj
0
3
5
🚨Time to rethink the SCS trial-to-implant ratio?🚨 With recent implant rates >80%, are trial-to-implant ratios are still meaningful? Or is it time to update utilization metrics to include explant and per-capita ratios? @DoctorSivaMD @Ryan_S_DSouzaMD
https://t.co/40BzXvytOu
rapm.bmj.com
The trial-to-implant ratio for spinal cord stimulation (SCS) has long served as a cornerstone metric for optimizing patient selection and cost containment. Historically, screening trials played a...
1
5
14
ASRA Pain Medicine consensus practice infection control guidelines for regional anesthesia and pain medicine https://t.co/ke9OBvpjyi
@ASRA_Society @RAPMOnline @DProvenzanoMD @SLKoppMD @dr_tinadoshi @AmyPearsonMD @amit_pawa @ajrmacfarlane @KalagaraHari @NarouzeMD @DoctorSivaMD
rapm.bmj.com
Background To provide recommendations on risk mitigation, diagnosis and treatment of infectious complications associated with the practice of regional anesthesia, acute and chronic pain management....
0
11
29
In @ScienceMagazine today, the discovery of the neuroimmune itch-scratch circuit. And why scratching can make things worse https://t.co/psn5XDuyD9
https://t.co/bq17rsEqwB
9
120
468
FDA approves new non-opioid pain drug https://t.co/IMJdd5OHJi The FDA has approved Vertex’s suzetrigine, an oral inhibitor of the ion channel NaV1.8, for the treatment of moderate to severe acute pain, providing a much-needed new option Background here https://t.co/w90YK8RJLy
6
132
306